Evaluation of the Effects of Q10 on Neural Protection and Behavioral Disorders in Cell Culture and Mice Models of Parkinson’s Disease

Subject Areas :

mahdieh Aazarshab ¹ , mehdi rahnema ² , Ramin Hajikhani ³ , Jalal Solati ⁴ , mohammad Reza Bigdeli ⁵

1 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Zanjan Branch, Islamic Azad University, Zanjan, Iran
3 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
4 - Department of Biology, Karaj Branch, Islamic Azad University, Karaj, Iran.
5 - Department of Biology, Faculty of Biological Science, Shahid Beheshti University, Tehran, Iran

Received: 2019-09-07 Accepted : 2019-10-22 Published : 2019-11-22

Keywords:

Abstract :

Inroduction & Objective: Oxidative stress which is responsible for pathophysiology of hypertension, causes decrease in total antioxidant capacity. PON 1 is an antioxidant enzyme present on the surface of HDL also which is responsible for prevention of HTN and it’s complications. The aim of this study was to investigate the Effect of Isosorbide and Garlic Supplementation on Protein levels and Gene expression of PON1 at the Heart tissue in Female rats with hypertension After a period of aerobic training. Materials and Methods: In the experimental study,30 female Wistar rats weighing 180-220 g were randomly divided into 8 groups: healthy control, sham, blood pressure induction (Hyper), garlic, endurance training, endurance training -garlic. The rats suffered from hypertension of 6 days a week for 8 weeks after dietary period and 10 mg/kg body weight L_NAME injection. Experimental groups received 50 mg/kg body weight garlic supplement for six weeks.The endurance training program was performed at speeds of 20-30 m/min and 20 to 35 minutes, 5 sessions per week for 6 weeks. Protein levels and expression of PON1 heart tissue were measured using ELISA kit and Real Time PCR. Data were analyzed by t-test, One-way ANOVA and post hoc tokey at the significant level P<0.05. Results: The results showed that there was no significant difference between the mean protein and the expression of paraoxonase-1 in the heart tissue of the female rats with hypertension in the different groups of the study (P> 0.05).Also, there was no difference between the levels of protein paraoxonase-1 heart tissue in different groups than the group of blood pressure induction (P> 0.05). Conclusion: According to the findings, it seems to that the inadequacy of the training period (frequency and intensity of exercise) and the dose rate of Garlic Supplementation can be one of the possible causes of ineffectiveness in the present study.  

References:

.Aly, N. (2012). Reno-protective efficiency of coenzyme Q10 on adriamycin-induced nephro toxicity in rats. J Appl Sci Res, 8; 589.

2.Beal, MF., Matthews, RT., Tieleman, A., Shults, CW. (1998). Coenzyme Q10 attenuates the 1-methyl - 4- phenyl -1,2,3,6- tetra hydropyridine(MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res, doi:10.1016/S0006-8993(97)01192-X.

3.Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R. (2001). Molecular pathways involved in the neuro toxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in neurobiology, 65; 135-172.

4.Crane, F.L. (2001). Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition, 20; 591-598.

5.De Luca, C., Kharaeva, Z., Raskovic, D., Pastore, P., Luci, A. (2012). Coenzyme Q10, vitamin E, selenium, and methionine in the treatment of chronic recurrent viral muco cutaneous infections. Nutrition, 28; 509-514.

6.Elbaz, A., Bower, J.H., Maraganore, D.M., McDonnell, S.K., Peterson, B.J., Ahlskog, J.E., Schaid, D.J. (2002). Risk tables for parkinsonism and Parkinson's disease. Journal of clinical epidemiology, 55; 25-31.

7.Hubble, J.P., Cao, T., Hassanein, R., Neuberger, J., Roller, W. (1993). Risk factors for Parkinson's disease. Neurology, 43; 1693-1693.

8.Lenaz, G., Fato, R., Castelluccio, C., Genova, M., Bovina, C., Estornell, E. (1993). The function of coenzyme Q10 in mito chondria. The clinical investigator, 71; S66-S70.

9.Lin, T. K., Liou, C. W., Chen, S. D., Chuang, Y. C., Tiao, M. M., Wang, P. W. (2009). Mito chondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Med J, 32; 589-599.

10.Mc Carthy, S., Somayajulu, M., Sikorska, M., Borowy-Borowski, H., Pandey, S. (2004). Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble coenzyme Q10. Toxicol Appl Pharmacol, 201(1); 21-31.

11.McGeer, P.L., Mc Geer, E.G. (2004). Inflammation and neuro degeneration in Parkinson's disease. Parkinsonism & Related Disorders, 10; S3-S7.

12.Ogura, Y., Takagi, K., Kawarada, Y., Mizumoto, R. (1996). Patho physiological effect of hepatic ischemia and reperfusion after hepatectomy in dogs with obstructive jaundice, focusing on the effect of coenzyme Q10 and styrene-co-maleic acid superoxide dismutase. J. Gastroenterol, 31(3); 379-86.

13.Ostrowski, R., Piotrowski, P., Pańkowska, T., Smiałek, M. (1998). Evaluation of morphological changes after treatment with coenzyme Q10 (CoQ10) in endothelin-1 induced experimental ischemia in the rat. Folia neuropathologica, 36; 185-188.

14.Overvad, K., Diamant, B., Holm, L., Hølmer, G., Mortensen, S., Stender, S. (1999). Coenzyme Q 10 in health and disease. European Journal of Clinical Nutrition, 53; 764.

15.PubMed – NCBI NeurouroL Urodyn. 2009, 28 (4); 339 – 42. doi : 10.1002/nau.20662

16.Savica, R., Rocca, W.A., Ahlskog, J.E. (2010). When does Parkinson disease start? Archives of neurology, 67; 798-801.

17.Schapira, A.H. (2009). Neurobiology and treatment of Parkinson's disease. Trends in pharmacological sciences, 30; 41-47.

18.Sohet, FM., Neyrinck, AM., Pachikian, BD.,de Backer, FC., Bindels, LB., Niklowitz, P.(2009). Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol, 78(11); 1391-400.

19.Thoenen, H., Tranzer, J. (1968). Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxy dopamine. Naunyn-Schmiedebergs Archiv für Pharmakologie und Experimentelle Pathologie, 261; 271-288.

20.Veldman, B., Wijn, A., Knoers, N., Praamstra, P., Horstink, M. (1998). Genetic and environmental risk factors in Parkinson’s disease. Clinical neurology and neurosurgery 100; 15-26.

21.Zhen, R., Wenxiang, D., Zhaokang, S., Xinling, G., Huiming, H., Jingfeng, L. (1994). Mechanisms of brain injury with deep hypothermic circulatory arrest and protective effects of coenzyme Q10. The Journal of thoracic and cardiovascular surgery, 108; 126-133.